Towards better healthcare access
Ministry, private hospital join hands to bring services to 12 villages in Kampar
UTAR Hospital is collaborating with Housing and Local Government Ministry (KPKT) in Perak to carry out the 'Kampungku' programme.
The initiative is aimed at enhancing healthcare accessibility and promoting preventive health awareness among communities in rural and underserved areas.
The hospital's management team is in a discussion with the heads of new villages to finalise the programme.
'Kampungku' is an initiative to enhance the well-being of residents in new villages and improve their quality of life.
The initiative, expected to commence this month, offers health screening services such as blood tests and specialist consultations to 12 selected villages in the Kampar area, including Malim Mawar, Chenderiang, Bidor and Tapah.
The programme will also include services from UTAR Hospital's Traditional and Complementary Medicine (TCM) Centre, incorporating traditional Chinese medicine such as acupuncture, tui na (massage) and gua sha (scrapping).
The collaboration, consisting of a series of educational talks and community outreach activities, seeks to promote not only the importance of regular health screenings but also healthy lifestyles and emergency preparedness.
UTAR Hospital chief executive officer and medical director Datuk Dr Ding Lay Ming said: 'Continuous healthcare education is crucial to raise awareness of preventive measures among the community.'
UTAR Hospital operation and business development director Abang Russaini Abang Zainal Abidin said, 'As the first private specialist hospital in Kampar, UTAR Hospital is uniquely and strategically positioned to extend not only healthcare and medical services but also healthcare awareness to surrounding areas, including the broader northern Perak region.
'This initiative reflects our core mission of 'Enriching and Caring for the Community'.'
In a media statement, the officials said the collaboration between the ministry and UTAR Hospital marked a significant milestone not only in expanding access to affordable and quality healthcare for rural communities, but also in demonstrating a shared commitment to the health and welfare of underserved populations.
'This collaboration also marks a promising and potential step toward future public-private collaborations, where private healthcare institutions can play a key role in supporting efforts to deliver affordable and quality healthcare services to the community,' the statement added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
17 hours ago
- The Star
Varsity students raise RM3,900 for hospital through plastic-free campaign
Chen (standing fifth from right) presenting the mock cheque to Prof Ewe (sixth from left) during the university's 40th convocation ceremony. A GROUP of graduates from Universiti Tunku Abdul Rahman's (UTAR) Public Relations programme donated close to RM4,000 to UTAR Hospital in Kampar. The 62 individuals raised RM3,858 through a corporate social responsibility (CSR) project called 'We Want No Plastic: We Are Fantastic Without Plastic'. Project director Chen Zhi Shan said a mock cheque presentation was held to hand over the funds to UTAR president Prof Datuk Dr Ewe Hong Tat was held during the university's 40th convocation ceremony. She said funds were raised through the sale of various items and community sponsorship. 'We sold fruits, yau char kwai (Chinese cruller), jelly, coffee and succulent plants. 'These items were packed in recyclable packaging or containers, which aligned with our campaign's goals,' she said, adding that it took about four months to raise the money. Chen said the group also sold merchandise such as tote bags and glass cups with glass straws to promote reusable items. 'The donation was also our way to give back to the community,' she said. The project, launched in June last year, was aimed at raising awareness of microplastic pollution, advocating for the reduction of single-use plastics as well as promoting healthier and more eco-friendly lifestyles. 'We were aware of the potential health risks posed by microplastics when preparing for this project, and this motivated us to make the project a reality. 'We hope that our efforts will not only impact the campus community but also raise broader awareness among the public,' said Chen. She said the group decided to donate the proceeds to the hospital as a gesture of gratitude. 'We want to give back to our alma mater and the community at large for their support in our academic journey. 'The donation supports the university's sustainability efforts and underscores its 'From Grads to Future Greats' message,' she added. In addition to expressing his gratitude for their contribution, Prof Ewe also congratulated the graduates on their achievement in securing UTAR's first-ever gold award in the Malaysia Public Relations Awards 2024 for their CSR project. ― By IVAN LOH
The Star
a day ago
- The Star
China donates medical equipment, supplies to Ghanaian hospital
ACCRA, June 16 (Xinhua) -- The Chinese government, through its 14th medical team to Ghana and in collaboration with the local Chinese business community, on Monday donated a range of medical equipment and supplies to Lekma Hospital in Accra, Ghana's capital, to enhance healthcare services. The donation, including ultrasound devices, transducers, surgical instruments, and other medical tools, is expected to boost the hospital's diagnostic and treatment capacity. Chinese Ambassador to Ghana Tong Defa described the gesture as another concrete support and action of love from the Chinese government and people to Ghana. "Healthcare cooperation is one of the key areas in China-Ghana relations. China is pleased to see that, through joint efforts, both sides have achieved fruitful results in epidemic prevention and control, vaccine rollout, and public health capacity building," Tong said at the donation ceremony. Ghana's Health Minister Kwabena Mintah Akandoh welcomed the donation as another shining example of the Ghana-China collaboration and "an enduring testament to the strength of our partnership." Akandoh lauded the Chinese government for sending 14 medical teams to Ghana since 2009. As Ghana seeks to achieve universal health coverage by 2030, the minister said cooperation with China remains vital. "When we talk about herbal medicine, innovation, infrastructure, and financing facilities, it is China that comes to mind," he said. Yang Yongguang, head of the 14th Chinese medical team to Ghana, said, "We stand ready to deepen the China-Ghana health cooperation through technology and resources, working hand-in-hand to forge a broad path towards health for all and shared prosperity."
The Sun
a day ago
- The Sun
U.S. drugmakers boost licensing deals with Chinese biotechs
U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals. 'WAKEUP CALL' By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
